Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

TG Therapeutics Inc's Ublituximab Receives Orphan Drug Designation For Treatment Of Nodal Marginal Zone Lymphoma And Extranodal Marginal Zone Lymphoma


Monday, 9 Sep 2013 07:30am EDT 

TG Therapeutics Inc announced that ublituximab (TG-1101), the Company's glycoengineered anti-CD20 monoclonal antibody has received two Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for the treatment of Nodal Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma (Mucosa-Associated Lymphatic Tissue, MALT), both rare subtypes of non-Hodgkin's lymphoma (NHL) for which there are limited effective treatments. 

Company Quote

8.255
-1.335 -13.92%
22 Jul 2014